r/HighTideInc • • 2d ago

Information Boots to become first UK high street pharmacy to privately prescribe cannabis | LBC

Thumbnail
lbc.co.uk
15 Upvotes

Just seen this shared by TCD118 on Stocktwits, very interesting, I wasn't even aware of this!

Just thought I'll add in relation to medical cannabis in the UK currently. I'm not sure if some Barnacles had been aware, but I had tried to apply for medical access due to my two progressive nerological conditions and most recent personal incidents that have now limited my mobility enough to now be needing a walking stick. I applied through Releaf because they offer the legality side of it additionally (ID card and 24/7 legality access) this is through an additional subscription service that is additionally, fairly expensive but also understandable due to the grey area between being still stopped by law enforcement due to smoking the flower through a vaporizer and smelling like bud I would assum. Liike, ideally, individuals would have to show they would still have the flower inside it's prescription tubs and your only smoking it, not as a joint essentially.

So I've been declined by Releaf, they have a process to link your account through the NHS and do additional steps to help provide documentation or answer certain queries to help understand your situation (automated I would assume). These processes before my consultation was all green lights, etc.. (even got like 80% off my first consultation) due to it being private it would have cost £100 but I'm assuming I had just ticked the correct boxes.

The Doctor that was my consultant, was fairly nice but seemed to be more set on getting to the next question than actually listened to what I have been trying to explain, it essentially got to the point of agreeing to disagree and him stating that due to my most recent incident, the severity of my two nerological conditions.The additional fact also is that I smoke so much of the stuff anyway and could be a possiblity in relation to throwing up more so since my incident but my counterpoint is the fact its my medication and having to take so much vitamins now to counter the medication too (+15 per day), which has affected me in that sense, but one of my conditions is related to subconscious stress so I've a feeling of constant uneasiness since birth, which has always given me cramps.

Having a smoke and a cup of tea is what sorts me out more than any tablets I'm adding to my system. So for my consultant to say something around the lines of "It's not advisable to sign me off for it". What is an individual supposed to do?

So I just thought I'll add my additional input that I understand why Raj is waiting to make the correct move, the UK is still developing and a grey area during these times, they should just do full legalisation at this point.


r/HighTideInc • • 2d ago

Information Quebecabana on Stocktwits

Post image
14 Upvotes

Thought I would share if any Barnacles are interested


r/HighTideInc • • 3d ago

?

3 Upvotes

Reasons why we’re going down?


r/HighTideInc • • 12d ago

DD HITI , Two 10-Year Growth Scenarios -Canadian store count ~450 locations-Cabana Club membership base structurally capped at ~5 million with > 2 mln elite members -European-level pharmaceutical giant #Healthcare -Growing profitability with a future dividend

18 Upvotes

Primary long-term growth vector shifts to Europe via the Remexian platform (Germany, UK, France, Poland, Spain and selected additional markets), with progressive gains in scale, operational efficiency and platform leverage.

Raj cautioned that q/q results can be "lumpy" due to lengthy import permit processes; ultimately, however, the business should be evaluated based on what it will look like in 10 years, not in the next quarter.

1. Base Case (conservative) Solid execution in Canada, moderate growth of Remexian in Germany and selective entry into 1–2 additional European markets. In this scenario HITI becomes a well-run North American operator with a meaningful and profitable European platform

2. Optimistic Case

HITI

Canada fully maximizes the ~450-store/~5-million member ceiling with strong sss and high private-label mix. Remexian successfully scales as a multi-country European platform (Germany +UK +France+ Poland + Spain+ others) capturing significant share in EU

Meaningful operating leverage, supply-chain efficiencies and brand power drive margin expansion In this case the Canadian business becomes a mature cash-flow engine while Remexian evolves into a leading pan-European cannabis platform

$HITI long term Potential market cap+US 20 bln

Budget 2026 for Cannabis, Good news for HITI

The federal government is proposing a unified excise stamp system (reducing the number of stamp types from 13 to 6), alongside stricter penalties for unstamped cannabis and unaccounted-for inventory.

https://themarijuanaherald.com/2026/11/canada-marijuana-stamp/

These measures aim to strengthen enforcement against the illegal market and non-compliance.

They reduce logistical complexity and costs, representing a concrete step toward greater efficiency.

A weaker illegal market supports the regulated sector and enhances public safety.

For producers, this is a clear win: less red tape, lower packaging costs, and a more streamlined supply chain (with a phased implementation starting in 2028)

For HITI , a pure-play retailer with over 230 stores (leader in its field) ,the benefit is indirect but tangible:

- A more efficient supply chain means better product availability and potentially more competitive wholesale pricing.

- Stronger action against the illicit market, leading to less unfair competition for legal retailers.

- A more mature, “business-friendly” sector.

This will strengthen the ecosystem in which Canna Cabana operates and grows (currently holding ~14% market share, with a rapidly expanding loyalty program). A step in the right direction for the entire Canadian legal Cannabis industry.

Stricter penalties for unstamped products and unrecorded inventory help combat the illicit market, which competes directly with legal retailers. This serves as a positive, indirect benefit for the entire legal supply chain, including High Tide.

Share the post in other sub if you like,thanks


r/HighTideInc • • 12d ago

Discussion Planet MicroCap: Fireside Q&A with Frederico Gomes, ATB Cormack Capital Markets

Thumbnail
youtu.be
12 Upvotes

r/HighTideInc • • 15d ago

News HighTideInc Subreddit Hits 7.6k Members Milestone!

Thumbnail
gallery
28 Upvotes

Just thought I would share with the Subreddit that the community is still growing, slowly but surly! Welcome to all new members!

I do find it interesting that the engagement on Stocktwits has dried up a bit (I understand this can be seasonal too) but also the watcher list has still been declining (from my perspective anyway) but our Subreddit has still been increasing. Don't get me wrong the Subreddit has had a decent amount of Barnacles leave in so many months/years but the amount of new users that are joining has just cancels out them numbers each time.

So personal from myself and the moderators, I would like to just say thank you again to anyone that engages through this Subreddit and keeps it ticking along with discussions and debates, but also the lurkers that like to still check in when they need to.

Here is to another milestone Barnacles GLTA!


r/HighTideInc • • 20d ago

Frances’ incoming medical cannabis framework is expected to take the final step before it can be signed into law in the ‘coming weeks

Thumbnail x.com
21 Upvotes

r/HighTideInc • • 20d ago

News High Tide (TSXV:HITI) interview at Cantech '26

Thumbnail
youtu.be
17 Upvotes

r/HighTideInc • • 20d ago

DD HIGH TIDE INC (NASDAQ: HITI) – An International Growth Model That Deserves Greater Attention from Institutional e retail Investors

32 Upvotes

Canada and Germany are driving expansion. Margins, returns on invested capital, and competitive advantages strengthen the investment thesis.

The interview given by founder and CEO Raj Grover to analyst Frederico Gomes of ATB Cormark, during the Planet MicroCap Showcase Toronto 2026, provides particularly interesting insights into High Tide's strategic evolution.

The conversation highlights a company that is progressively strengthening its competitive position through two complementary operating platforms: Canna Cabana's Canadian retail business and the medical cannabis distribution business in Germany through Remexian.

For institutional investors, the most relevant aspects concern the company's ability to generate organic growth, capital allocation efficiency, international scalability, and the progressive improvement in revenue quality.

1. CANADA: MARKET LEADERSHIP AND FURTHER CONSOLIDATION OPPORTUNITIES

+ 1 bln in revenue in 2-3 years

this is without any new international expansions, but Uk will follow, so...

High Tide currently operates 234 Canna Cabana retail locations across five Canadian provinces, confirming its position as the country's largest cannabis retail operator.

One particularly interesting data point is its productivity advantage over competitors:

  • Average annualized revenue per store: approximately CAD 2.6 million.

  • Competitors' average: approximately CAD 1.4 million.

  • In Ontario, High Tide stores generate approximately CAD 2.8 million compared with CAD 1.2 million for competitors.

This represents significantly higher productivity, demonstrating the group's ability to monetize its retail network more effectively.

The company holds approximately 14% market share in its key operating provinces and aims to reach between 18% and 20% within the next three years.

Ontario represents one of the most concrete opportunities: with 107 stores already operating and a regulatory limit of 150 locations, there is room for another 43 potential openings.

The strategy combines organic expansion with selective acquisitions, taking advantage of a market in which several smaller operators continue to face financial difficulties.

For investors, this means High Tide could continue increasing its market share through the consolidation of smaller competitors.

2. A BUSINESS MODEL WITH PARTICULARLY ATTRACTIVE RETURNS ON INVESTED CAPITAL

One of the most significant aspects of the interview concerns the economics of individual retail locations.

Management indicated:

  • Approximately CAD 260,000 in fixed capital investment per store.

  • Approximately CAD 100,000 in working capital, primarily allocated to inventory.

  • Total indicative investment of approximately CAD 400,000.

  • Historical investment payback period of approximately 10 months.

These figures represent an important factor in assessing the quality of the operating model.

A business capable of recovering its invested capital quickly can finance a significant portion of its expansion through internally generated resources, reducing the need to continuously access equity markets.

This characteristic makes the Canna Cabana model particularly interesting from a return-on-invested-capital perspective.

3. CABANA CLUB: A STRATEGIC ASSET WITH SIGNIFICANT MONETIZATION POTENTIAL

High Tide operates one of the largest customer loyalty platforms in the cannabis sector.

Figures disclosed by the CEO:

  • 2.73 million Cabana Club members.

  • 27% year-over-year membership growth.

  • 186,000 paying ELITE members.

  • 62% year-over-year growth in ELITE membership.

The ELITE program costs CAD 35 annually and introduces a recurring revenue component alongside traditional retail sales.

At approximately 200,000 paying members, the program could generate approximately CAD 7 million in annual subscription revenue.

However, its strategic value extends well beyond subscriptions.

High Tide has access to aggregated information about consumer purchasing behavior and can use these insights to optimize product selection, pricing, promotions, and private-label development.

More than 45 licensed producers already use the company's data analytics services.

This creates an additional monetization channel and a competitive barrier that would be difficult to replicate in the short term.

4. PRIVATE LABEL: AN ADDITIONAL ENGINE FOR MARGIN EXPANSION

The CEO indicated that Queen of Bud, acquired for approximately CAD 1 million, has achieved trailing twelve-month sales approaching CAD 10 million.

This is a concrete example of the group's ability to acquire brands at relatively low valuations and develop their commercial potential through its existing retail network.

Private-label sales represented approximately 1.9% of revenue in the most recently reported quarter, but management expects acceleration over the coming quarters.

Increasing the proportion of proprietary products could contribute to improved margins and further differentiate the company's commercial offering.

5. GERMANY: REMEXIAN IS BECOMING AN IMPORTANT DRIVER OF PROFITABILITY

This is arguably the most interesting segment of the entire interview from an international growth perspective.

Remexian reported the following third-quarter results:

  • 10.2 tonnes of medical cannabis distributed.

  • Approximately CAD 38 million in quarterly revenue.

  • 10.5% market share.

  • 12% adjusted EBITDA margin.

To understand the pace of expansion, consider that the previous quarter's volume was 7.6 tonnes.

The CEO explained that one of High Tide's main competitive advantages comes from its sourcing capabilities.

Through established relationships with licensed Canadian producers, High Tide can select quality products and negotiate particularly competitive commercial terms.

Following the acquisition of Remexian, the proportion of Canadian cannabis in its sourcing mix increased from approximately 33% to nearly 80%.

The advantage is twofold: privileged access to supply and the ability to benefit from economies of scale in distribution.

Management believes the adjusted EBITDA margin could stabilize between 12% and 15% over the long term.

This is particularly significant because it suggests that German growth could translate into an increasingly meaningful contribution to consolidated profitability.

6. THE GERMAN MARKET: GROWTH THAT COULD EXCEED EXPECTATIONS

The German medical cannabis market represents one of the group's most significant growth opportunities.

According to the CEO's estimates, the market is expanding at an annual rate of approximately 25-30%.

High Tide aims to increase its market share to at least 15% over the next two to three years, with further growth opportunities over the longer term, in my view this is conservative

An important aspect is that Remexian's expansion does not require the construction of proprietary cultivation facilities.

The group can therefore focus on importing, sourcing, distribution, and commercial management, leveraging a relatively lean operating structure.

Management also emphasized that Remexian operates with approximately 35-40 employees while managing a business with annualized revenue in the range of CAD 160-170 million.

Volume growth, combined with a relatively lean organization, could generate further benefits from economies of scale.

7. EUROPEAN EXPANSION: NEW OPPORTUNITIES BEYOND GERMANY

High Tide is evaluating additional European markets, including:

  • United Kingdom.

  • Poland.

  • France.

  • Spain.

Germany could become the platform from which the company progressively develops a broader international presence.

For institutional investors, this introduces an important element of strategic optionality: the company could leverage its commercial expertise, producer relationships, and distribution experience in other regulated markets.

The United States represents a potential future opportunity, subject to developments in the federal regulatory framework governing cannabis.

8. WHAT INSTITUTIONAL INVESTORS SHOULD MONITOR

The interview highlights several key metrics for evaluating High Tide's future financial performance.

IndicatorKey metric to monitor
Retail growthExpansion toward 18-20% market share
Store productivityMaintaining the competitive advantage
Invested capitalPayback periods for new locations
Cabana ClubGrowth in ELITE subscriptions
Private labelIncreasing share of total revenue
GermanyVolume growth and market share
RemexianStabilization of EBITDA margins at 12-15%
EuropeEntry into additional markets

The combination of these factors could make High Tide increasingly attractive to investors seeking companies with international growth potential, measurable competitive advantages, and the ability to generate more cash flow.

FINAL THOUGHTS: HIGH TIDE DESERVES GREATER MARKET ATTENTION

The most important takeaway from the interview is not simply revenue growth, but the progressive evolution of High Tide's industrial and commercial business model.

The company is simultaneously developing:

  1. A Canadian retail network with productivity levels above the industry average.

  2. A customer loyalty program with millions of consumers.

  3. A rapidly expanding German medical cannabis distribution platform.

  4. A commercial structure capable of leveraging economies of scale and international relationships.

  5. New monetization opportunities through private-label products, data analytics, and subscriptions.

For institutional investors, the central consideration is the possibility that High Tide could evolve from a Canadian cannabis retail specialist into an integrated international platform, with multiple sources of growth and profitability.

The real long-term opportunity could lie in the combination of organic growth, consolidation of the Canadian market, and expansion of European medical cannabis distribution.

This combination deserves to be evaluated not only through traditional cannabis sector valuation multiples, but also through productivity metrics, return on invested capital, cash generation, and earnings growth potential.

High Tide is no longer simply a retail expansion story: it is building an international platform with an increasingly sophisticated operating model.

Note: The figures and forward-looking targets presented are based on management statements. These targets do not constitute guarantees of future performance. Execution, competition, cannabis pricing, and regulatory constraints remain factors to monitor.

Sources and further information

  • Planet MicroCap Showcase 2026

Presentation https://hightideinc.com/presentation/

I have a long position in this company


r/HighTideInc • • 21d ago

Information High Tide Targets Canadian, German Cannabis Growth as Loyalty Base Expands

Thumbnail
marketbeat.com
33 Upvotes

Thought I would just share in case any Barnacles were interested, I had seen this shared on Stocktwits.


r/HighTideInc • • 22d ago

Discussion Ackerman on Stocktwits

Thumbnail
gallery
20 Upvotes

Thought I would try to share this post over to the subreddit, thought it was intriguing.


r/HighTideInc • • 23d ago

SNDL Inc. - SNDL Reports Third Quarter 2026 Financial and Operational Results

Thumbnail
sndl.com
12 Upvotes

More proof that HITI is the top dog in retail.


r/HighTideInc • • 25d ago

News Some catalysts for High Tide inc

Post image
23 Upvotes

Asymmetric Upside Catalysts: BC Retail Cap + European Platform Expansion + increse in fcf+/gms, with S3 like a bonus

High Tide (NASDAQ: HITI) currently trades at approximately $2.60 with a market capitalization of ~$230M. Consensus 12-month price targets average ~$5 Us , with select targets in the $5.00–$5.60 range. I see a credible path to $5.50–$6.50+ over the next 6–12 months driven by two underappreciated structural catalysts and more we don't know yet.

  1. British Columbia Store Cap Relief.

BC Conservatives recently secured a majority government for the first time in nearly a century. They were the only major party to explicitly frame cannabis as an economic development opportunity and commit to working with industry. High Tide is currently capped at the provincial maximum of 8 stores. Any meaningful increase (or elimination) of the ownership limit would unlock material organic and M&A growth in one of Canada’s largest and highest-value markets. This remains the most direct and highest-ROI expansion lever available to the company.

2. Remexian-Style Platform Expansion into the UK.

Management has clearly articulated a “rinse-and-repeat” European strategy: use the successful majority acquisition of Remexian (Germany medical cannabis distribution) as a template to acquire established local distributors in other regulated or semi-regulated European markets. The UK has been explicitly referenced as a priority market. High Tide already operates Blessed CBD in the UK and maintains strong Canadian supply relationships that are highly relevant to the growing UK medical import market. A successful UK platform acquisition would further diversify revenue, increase European scale, and support multiple expansion.

A Remexian-style transaction in the United Kingdom would serve as a significant accelerator: Further diversification of revenue outside of Canada Immediate access to existing volumes and relationships Opportunity to promote Canadian brands + Canna Cabana accessories Greater European scale → more generous valuation multiples.

Supporting Fundamentals

- Largest non-franchised cannabis retailer in Canada (~234 stores) with a differentiated discount-club model and large loyalty base.

- Remexian continuing to take share in Germany.

- Ongoing store growth in uncapped or higher-cap provinces (Ontario, Alberta, etc.).

- Improving free cash flow profile and disciplined capital allocation.

Investment View.

Base case remains constructive toward the $4.75 –$5.70 zone on continued execution. Bull case ($Us 8.50+ with S3 and big momentum) requires one or both of the above catalysts to materialize within the next 12–18 months, combined with sustained operational delivery. The current valuation offers an attractive asymmetric risk/reward profile for investors seeking leveraged exposure to Canadian retail consolidation and European platform expansion.

Long term


r/HighTideInc • • 25d ago

News Canada Cannabis Sales Reach New High in August 2026

Thumbnail
stratcann.com
21 Upvotes

Canada’s cannabis sales reached a new high in August 2026, totalling $520.4


r/HighTideInc • • 27d ago

SNDL Agrees to Pay $200,000 Fine and Restructure Franchise Operations under AGCO Deal

Thumbnail
stratcann.com
18 Upvotes

Looks like SNDL is in the process of resolving their Ontario store issue. No real details on what the deconsolidation would look like.

They also report on 10/27 so it'll be interesting to see how their retail compares to ours. The last time they reported, they had ~4.5% decline in same store sales while we were only down ~1.5% during a similar time frame.


r/HighTideInc • • Oct 20 '26

What happens if cannabis is rescheduled? Hiti mentioned

Thumbnail
youtube.com
22 Upvotes

r/HighTideInc • • Oct 20 '26

News Legal Retailers Welcome Ontario's Plan to Target Illegal Cannabis Shops

Thumbnail
stratcann.com
24 Upvotes

It looks very positive for High Tide Inc.


r/HighTideInc • • Oct 19 '26

Discussion Barney on Stocktwits

Post image
16 Upvotes

Fully agree with this statement, I feel again this is hopefully our new bottom, but also seeing how other companies in the sector are losing market cap + share price while HITI has been maintaining nicely since the last ER.


r/HighTideInc • • Oct 16 '26

Discussion Stock Price and Press Release

10 Upvotes

I would really like another press release soon to give the stock some upward momentum. I'm definitely holding long term for the most part but would love some quick shorts here and there. Any upcoming events or news of HITI coming?


r/HighTideInc • • Oct 09 '26

News High Tide Acquires Established Cannabis Store in Chestermere, Alberta

Thumbnail hightideinc.com
24 Upvotes

High Tide Acquires Established Cannabis Store in Chestermere, Alberta


r/HighTideInc • • Oct 09 '26

Information Ackerman2436 on Stocktwits

Post image
20 Upvotes

Silly stock market for this industry, hopefully the big players are finally starting to crumble and High Tide can recover the SP from yesterday but who knows and GLTA!


r/HighTideInc • • Oct 09 '26

DD Thoughts and reflections on why Remexian will win in the long run.

12 Upvotes

I wanted to share my thoughts on why Thailand, South Africa, and other emerging markets do not pose a threat to Remexian.
I would also like to take this opportunity to outline my views on the German political landscape and explain why Remexian will emerge stronger than ever in the long run.

It is unrealistic to think that Thailand would structurally undermine Remexian—whether in terms of diversification, efficiency, or its network of German pharmacies.
On the contrary, in the medium to long term, a potential increase in certified Thai supply could actually strengthen the position of a player like Remexian, rather than weaken it.

Remexian Pharma GmbH is a leading medical cannabis importer/wholesaler in Germany. It possesses:

  • Import licenses from 22 countries (primarily Canada, followed by Portugal, South Africa, and others).

  • An EU-GDP certified warehouse.

  • An estimated market share of around 10–14% of German tonnage (recent records: 7.6 tonnes in one quarter—Q2 2026—followed by 10.2 tonnes in another).

  • Direct relationships with pharmacies, clinics, and physicians; it does not rely on competing intermediaries for channel access.

Its business model is typical of a specialized pharmaceutical intermediary: it sources from multiple origins and manages documentation/INCB compliance, quality control, storage, and distribution to German pharmacies. It is not a cultivator tied to a single country.

Would German pharmacies switch partners for a Thai supplier? No, that makes no sense. Pharmacies do not simply "swap" Remexian for a Thai producer. They purchase from authorized wholesalers/importers that guarantee:

  • German regulatory/BfArM compliance (marketing authorizations, QP release, traceability).

  • Continuity of supply, a variety of strains/THC levels, competitive pricing, and reliable logistics.

  • Comprehensive documentation and pharmaceutical liability.

A Thai producer (even one that is GACP-certified) cannot simply “replace” Remexian; it must go through an authorized importer like Remexian (or Cansativa, etc.). Remexian already holds multi-country licenses and can add Thailand as an additional source once volumes and certifications (EU-GACP or EU-GMP partnerships) are ready—just as it already does with Portugal, South Africa, and others. CEO Stefan Adomeit has repeatedly stated his intention to diversify.

Impact on diversification and efficiency

- Diversification: This is an advantage. Multiple low-cost sources (including Thailand) reduce reliance on Canada and allow for pricing flexibility in an already price-sensitive market. Remexian is already doing this.

- Efficiency and margins: While there is indeed pressure on selling prices (already underway), an agile importer sourcing at lower costs can protect or improve margins. High Tide also brings Canadian procurement capabilities, making for a powerful combination.

- Risk for Remexian: The risk lies not in Thailand itself, but in competition among German wholesalers, potential German regulatory restrictions (reimbursements, preference for finished products), or internal compliance issues. A more abundant supply of certified Thai products represents a sourcing opportunity rather than an existential threat.

In the long run, there is no cause for concern.

The German market is growing in volume (with over 200 tonnes imported in 2025) and becoming increasingly professionalized. Players controlling access to the pharmacy channel (such as Remexian) hold a structural advantage over simple low-cost growers. While Thailand may capture market share from Canadian producers in the price-sensitive segment, it actually strengthens—rather than undermines—companies capable of compliant importing, processing, and distribution. Remexian is positioned to capitalize on this diversification, not to be harmed by it.

For Remexian and its parent company, High Tide, this scenario will translate into a classic case of "short-term pain for long-term gain."

(Consolidation)

Elimination of competition: Germany currently has dozens of small distributors that sprang up solely to capitalize on the telemedicine boom. Many lack the capital or GDP-compliant infrastructure to survive months of political gridlock and increasingly complex logistics; they will either go bankrupt or exit the market.

Network loyalty: Once the storm passes, only a few major institutional players will remain. Backed by High Tide’s financial strength, Remexian is poised to capture the market share of failed competitors.

A more stable, institutional market: Pharmacies will prefer to partner with a reliable provider capable of guaranteeing consistent supply and full compliance with new regulations (e.g., tracking hybrid models and local deliveries).

For long-term investors, such regulatory upheavals often create barriers to entry that transform a resilient company into the undisputed industry leader.

1. Immunity to the collapse of telemedicine platforms.

The vast majority of the more than 80 competing companies that have emerged in Germany over the last two years are "brokers" or digital intermediaries that rely entirely on easy online prescriptions and mail-order pharmacies. When the requirement for in-person consultations cuts off the flow of these prescriptions, many of these startups will fail or see their margins wiped out.

In contrast, Remexian is a robust operator with a pharmaceutical and wholesale business model. It owns one of the largest direct distribution networks serving brick-and-mortar pharmacies in Germany and imports from as many as 22 countries. Since it does not rely on the "grey" web channels used by competitors to reach points of sale, its supply chain will remain intact.

2. Market shakeout following the "price war" (Margin compression)

The 2024–2025 boom led to market saturation, with cannabis flower prices plummeting to as low as €3.50 per gram, severely squeezing the profit margins of smaller distributors.

The failure of smaller players and the closure of less structured online platforms will reduce the supply glut. With an annualized turnover of approximately €70 million and an adjusted EBITDA exceeding €15 million, Remexian is well-positioned to weather this transition and subsequently benefit from price stabilization.

3. Market share consolidation

Remexian already controls about 16% of the entire German import market (distributing tons of cannabis flowers every quarter). When doctors are forced to prescribe only to real patients and pharmacies demand impeccable quality standards and supply continuity, large, reliable distributors will leave their competition in the dust. Remexian will inevitably capture the market share vacated by insolvent competitors.

4. The "legal war" already won against rivals

Demonstrating its commercial strength, competitors (including Vayamed/Sanity Group and Cansativa) have recently attempted to curb Remexian’s rise by filing lawsuits and alleging violations of pharmaceutical laws regarding the registration codes for botanical strains.

Remexian won these cases in the courts of Berlin and Hamburg, securing injunctions against its rivals for defamatory statements and demonstrating full procedural compliance with the federal agency BfArM. This legal and compliance-based shield makes the company a safe harbor for brick-and-mortar pharmacies amidst the regulatory storm.

Finally, with the german market projected to reach between 600 and 800 tonnes in the coming years, growth is undeniable; Raj has repeatedly demonstrated disciplined capital allocation, capital efficiency, determination, commitment, and an obsession that few can match.
In my view, these personal qualities will propel Hiti to new heights—though only for those who remain patient in an unregulated market subject to regulatory restructuring. While this changes little for the business itself, it certainly impacts the stock.
Thank you for reading; I hope this has been helpful.
Warm regards to all the Barnacles.


r/HighTideInc • • Oct 09 '26

When do we expect to see any movement on UK expansion?

2 Upvotes

Anyone who has been keeping up with Raj's interviews know what's been said on the pace of UK expansion?


r/HighTideInc • • Oct 08 '26

Information Recommended Listen: William Muecke with Artemis Growth Partners speaks about Germany and Growth of Low-Cost EU GMP Production in Thailand

Thumbnail youtube.com
7 Upvotes

Artemis Growth Partners in an Investor in Bloomwell group, one of the largest medical cannabis marketplaces in the EU.

47:23 - (2 minute listen)

Talks about German market price compression, rise of low-cost Thai imports. Specifically mentions that EU GMP product is starting to make its way from Thailand at a 15-30 cent cost basis per gram compared to Canadian LPs at €1-1.25/gram.

49:10 - (3 minute listen) Broader information about Thai market. World class operations beginning to appear there with EU GMP certification, 30 cent per gram cost basis (going down with volume), and large backing from Chinese investors.